The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2016

Filed:

Nov. 20, 2012
Applicants:

The Scripps Research Institute, La Jolla, CA (US);

Ember Therapeutics, Inc., Boston, MA (US);

Inventors:

Theodore Mark Kamenecka, Palm Beach Gardens, FL (US);

Patrick R. Griffin, Jupiter, FL (US);

Amy S. Ripka, Reading, MA (US);

Jeffrey O. Saunders, Lincoln, MA (US);

Assignees:

The Scripps Research Institute, La Jolla, CA (US);

Ember Therapeutics, Inc., Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 235/08 (2006.01); C07D 403/10 (2006.01); C07D 235/06 (2006.01); C07D 401/06 (2006.01); C07D 401/10 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 403/10 (2013.01); A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01); C07D 235/06 (2013.01); C07D 235/08 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01);
Abstract

The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.


Find Patent Forward Citations

Loading…